Big-money shopping spree
Prosight appears to have taken a pretty serious swing at GeneDx Holdings, picking up 468,463 shares worth an estimated $42.72 million based on average first-quarter 2026 prices. That’s not a casual nibble at the buffet — that’s a full plate, maybe two.
Why investors care
When a healthcare investor adds that kind of size, the market usually asks the obvious question: what does the buyer see that everyone else might be missing? Maybe it’s GeneDx’s volume growth, maybe it’s the genomics tailwind, or maybe Prosight thinks the story still has runway.
Either way, the signal is simple: someone with money on the line decided GeneDx was worth a much bigger bet.
The catch
This is still a position change, not a guarantee that the stock is headed for the moon. Funds can be early, wrong, or just playing a longer game than the rest of us.
But in a market that loves a clue, a $42.7 million clue is hard to ignore. Big picture: when institutional money leans in, investors usually lean in to check the thesis.